Sign up for free TCR email newsletter

Sunday, June 23, 2024
Stephane Budel
Stephane Budel


Stephane Budel is more than a founding Partner at Decibio; a seasoned entrepreneur and veteran of the life sciences industry, he has worked to develop the new frontier in genomics and gene sequencing, working with dozens of clients in the research tools and clinical diagnostics fields. In addition to his pioneering work with the firm he launched in 2009, he was the senior life science specialist at L.E.K. Consulting for two years and was founder and chief scientific officer of Living Rox, Inc. Budel holds a master’s degree in physiology from the University of Geneva and a Ph.D. in neurology from Yale University.

Areas of expertise

Research tools and clinical diagnostics industry, Corporate strategy, product strategy, and transaction supports

Group Overview

As the pace of innovation in precision therapies accelerates, so do the challenges in bringing these transformative therapies to patients. Navigating evolving clinical trial, regulatory, manufacturing, and market access landscapes requires precise market insights and novel strategies. Client examples include: Biopharma Genomic Testing Market Research Clinical, Genomic, and Pathology Real-World Data (RWD) Market Landscape Assessment Internal Lab Buildout Strategy Synthetic mRNA Production Landscape Assessment

Firm Overview

DeciBio is a strategy consulting and market intelligence firm serving clients across the precision medicine ecosystem. DeciBio’s mission To accelerate the adoption and impact of precision medicine Precision medicine is a complex and rapidly-evolving field, requiring focus and attention to detail in order to keep up with the pace of innovation. With DeciBio’s specialized team of life science experts, DeciBio focuses on the precision medicine space. Working across the entire precision medicine value chain—from early-stage research to commercialization and the patient journey—gives DeciBio a uniquely comprehensive perspective. Consequently, DeciBio understands how market developments propagate throughout the precision medicine ecosystem. DeciBio Consulting is a boutique strategy consulting firm focusing on the life science industry. DeciBio's mission is to provide the strategic insights that accelerate the development, adoption, and accessibility of personalized medicine. Headquartered in Los Angeles, CA, DeciBio serves clients and customers across the globe, ranging from incubator-stage startups to Fortune 500 life science corporations. DeciBio addresses business solutions that range from market landscape analyses to full commercial strategies, including organic and inorganic growth opportunities (commercial due diligences). DeciBio’s work is typically supported by a mix of primary and secondary research leveraging Dexter, its in-house expert network, and DeciBio Analytics’ proprietary data intelligence products. DeciBio’s Analytics division offers numerous data products to support strategic insights, including in clinical diagnostics (the DxBooks), immuno-oncology (the I/O BioMAP), omics market segmentation (the MarketBooks), and the entire life sciences industry (BioTrack). Internal teams such as the Culture Committee, Women* in Consulting, and Gays in Consulting enrich the employee experience. DeciBio’s Social Impact board and the DeciBio Impact Lab work collaboratively across divisions and externally to uproot discrimination and increase access to precision medicine.